Zymeworks reports positive phase 1 data for cancer drug ZW191

April 21, 2026 5:30 PM

Zymeworks Inc. (NASDAQ: ZYME) announced results from a phase 1 study of ZW191, an antibody-drug conjugate targeting folate receptor alpha ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found